Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis.

doi:10.1136/jitc-2020-001955

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis.

Journal for immunotherapy of cancer - 1 Apr 2021

Knitz Michael W, Bickett Thomas E, Darragh Laurel B, Oweida Ayman J, Bhatia Shilpa, Van Court Benjamin, Bhuvane Shiv, Piper Miles, Gadwa Jacob, Mueller Adam C, Nguyen Diemmy, Nangia Varuna, Osborne Douglas G, Bai Xiyuan, Ferrara Sarah E, Boss Mary-Keara, Goodspeed Andrew, Burchill Matthew A, Tamburini Beth A Jirón, Chan Edward D, Pickering Curtis R, Clambey Eric T, Karam Sana D

Abstract excerpt

BACKGROUND: Numerous trials combining radiation therapy (RT) and immunotherapy in head and neck squamous cell carcinoma (HNSCC) are failing. Using preclinical immune cold models of HNSCC resistant to RT-immune checkpoint inhibitors, we investigate therapeutic approaches of overcoming such resistance by examining the differential microenvironmental response to RT. METHODS: We subjected two HPV-negative orthotopic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Basic-Leucine Zipper Transcription Factors

Share to Immune Checkpoint Inhibitors

Share to Interleukin-2 Receptor alpha Subunit

Share to Lymphocyte Depletion

Share to Radiation Tolerance

Share to Squamous Cell Carcinoma of Head and Neck

Share to Tumor Burden

Source

Open in PubMed Open full text

Identifiers

PMID: 33883256
DOI: 10.1136/jitc-2020-001955
PMCID: PMC8061827

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis.PMID 33883256Read ↗

Lymphatic-Preserving Treatment Sequencing with Immune Checkpoint Inhibition Unleashes cDC1-Dependent Antitumor Immunity in HNSCCSemantic proximity Read ↗

Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer respondersSemantic proximity Read ↗

Th2 cells are associated with tumor recurrence following radiation.Semantic proximity Read ↗

Connecting Baseline Immune Exhaustion in Hot Tumors to Oral Cancer Recurrence and Nodal MetastasisSemantic proximity Read ↗

Divergent response to radio-immunotherapy is defined by intrinsic features of the tumor microenvironmentSemantic proximity Read ↗

Tumor-educated VEGFR-3 lymphatics augment PD-1 resistance in HPV-negative HNSCCSemantic proximity Read ↗

Addition of chemotherapy to radiotherapy promotes progenitor-exhausted CD8⁺ T-cell clonal dominance in head and neck cancerSemantic proximity Read ↗

Why responses to immune checkpoint inhibitors are heterogeneous in head and neck cancers: Contributions from tumor-intrinsic and host-intrinsic factorsSemantic proximity Read ↗

A conserved subset of cold tumors responsive to immune checkpoint blockadeSemantic proximity Read ↗

Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.Semantic proximity Read ↗

Smyd3-mediated immuno-modulation in HPV-negative head and neck squamous cell carcinoma mouse modelsSemantic proximity Read ↗

Radiotherapy combined with docetaxel alters the immune phenotype of HNSCC cells and results in increased surface expression of CD137 and release of HMGB1 of specifically HPV-positive tumor cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.